APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Osteoarthritis Pain Drugs

The main role of osteoarthritis pain drugs is to relieve pain, and cannot slow the progress of osteoarthritis, osteoarthritis in the use of two kinds of painkillers.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

The main role of osteoarthritis pain drugs is to relieve pain, and cannot slow the progress of osteoarthritis, osteoarthritis in the use of two kinds of painkillers.

Selected research

Market Structure

Global Osteoarthritis Pain Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 17402085032 January 2026195 pages

Choose your research edition.

Industry ResearchOsteoarthritis Pain Drugs Industry Research Report 2026149 pages · $2,950 USDIndustry Growth & TrendsGlobal Osteoarthritis Pain Drugs Industry Growth and Trends Forecast to 2032128 pages · $3,450 USDMarket StructureGlobal Osteoarthritis Pain Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Osteoarthritis Pain Drugs Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Osteoarthritis Pain Drugs Market Analysis and Forecast 2026-2032212 pages · $4,950 USD

Market perspective

The main role of osteoarthritis pain drugs is to relieve pain, and cannot slow the progress of osteoarthritis, osteoarthritis in the use of two kinds of painkillers.

The major players in global Methylcyclohexane market include Pfizer, Johnson & Johnson, GlaxoSmithKline, etc. The top 3 players occupy about 45% shares of the global market. North America and Europe are main markets, they occupy about 70% of the global market. Oral is the main type, with a share over 50%. Personal Care is the main application, which holds a share about 90%.

This report provides an overview of the global Osteoarthritis Pain Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Osteoarthritis Pain Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Osteoarthritis Pain Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Osteoarthritis Pain Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Osteoarthritis Pain Drugs Segment by Company

Pfizer

Bayer

SK Chemicals

GSK

Sanofi

Crystal Genomics

Johnson & Johnson

Sino Biopharmaceutical

Haohai Biological

Zhejiang Chengyi Pharmaceutical

Freda

Bright Future

Jingfeng Pharmaceutical

Chugai Pharmaceutical

Mikasa Seiyaku

Taisho Pharmaceutical

Seikagaku Corporation

GlaxoSmithKline

Eli Lilly

Novartis

Horizon Pharma

Abbott

Mylan

Daiichi Sankyo

TEVA

Almatica Pharma

Astellas Pharma

Tide Pharmaceutical

Iroko Pharmaceuticals

Hengrui Pharmaceutical

Osteoarthritis Pain Drugs Segment by Type

Oral

Injection

External

Osteoarthritis Pain Drugs Segment by Application

Medical Care

Personal Care

Osteoarthritis Pain Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Osteoarthritis Pain Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Osteoarthritis Pain Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Osteoarthritis Pain Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Osteoarthritis Pain Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Osteoarthritis Pain Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Osteoarthritis Pain Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Osteoarthritis Pain Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Osteoarthritis Pain Drugs Industry Trends Table 2. Osteoarthritis Pain Drugs Industry Drivers Table 3. Osteoarthritis Pain Drugs Industry Opportunities and Challenges Table 4. Osteoarthritis Pain Drugs Industry Restraints Table 5. Global Osteoarthritis Pain Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Osteoarthritis Pain Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Osteoarthritis Pain Drugs Sales by Manufacturers (M Dose) & (2021-2026) Table 8. Global Osteoarthritis Pain Drugs Sales Market Share by Manufacturers Table 9. Global Osteoarthritis Pain Drugs Average Sales Price (US$/Dose) of Manufacturers (2021-2026) Table 10. Global Osteoarthritis Pain Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Osteoarthritis Pain Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Osteoarthritis Pain Drugs Manufacturers, Product Type & Application Table 13. Global Osteoarthritis Pain Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Osteoarthritis Pain Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Oral Table 17. Major Manufacturers of Injection Table 18. Major Manufacturers of External Table 19. Global Osteoarthritis Pain Drugs Sales by Type 2021 VS 2025 VS 2032 (M Dose) Table 20. Global Osteoarthritis Pain Drugs Sales by Type (2021-2026) & (M Dose) Table 21. Global Osteoarthritis Pain Drugs Sales by Type (2027-2032) & (M Dose) Table 22. Global Osteoarthritis Pain Drugs Sales Market Share by Type (2021-2026) Table 23. Global Osteoarthritis Pain Drugs Sales Market Share by Type (2027-2032) Table 24. Global Osteoarthritis Pain Drugs Revenue by Type 2021 VS 2025 VS 2032 (M Dose) Table 25. Global Osteoarthritis Pain Drugs Revenue by Type (2021-2026) & (M Dose) Table 26. Global Osteoarthritis Pain Drugs Revenue by Type (2027-2032) & (M Dose) Table 27. Global Osteoarthritis Pain Drugs Revenue Market Share by Type (2021-2026) Table 28. Global Osteoarthritis Pain Drugs Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Medical Care Table 30. Major Manufacturers of Personal Care Table 31. Global Osteoarthritis Pain Drugs Sales by Application 2021 VS 2025 VS 2032 (M Dose) Table 32. Global Osteoarthritis Pain Drugs Sales by Application (2021-2026) & (M Dose) Table 33. Global Osteoarthritis Pain Drugs Sales by Application (2027-2032) & (M Dose) Table 34. Global Osteoarthritis Pain Drugs Sales Market Share by Application (2021-2026) Table 35. Global Osteoarthritis Pain Drugs Sales Market Share by Application (2027-2032) Table 36. Global Osteoarthritis Pain Drugs Revenue by Application 2021 VS 2025 VS 2032 (M Dose) Table 37. Global Osteoarthritis Pain Drugs Revenue by Application (2021-2026) & (M Dose) Table 38. Global Osteoarthritis Pain Drugs Revenue by Application (2027-2032) & (M Dose) Table 39. Global Osteoarthritis Pain Drugs Revenue Market Share by Application (2021-2026) Table 40. Global Osteoarthritis Pain Drugs Revenue Market Share by Application (2027-2032) Table 41. Global Osteoarthritis Pain Drugs Sales by Region: 2021 VS 2025 VS 2032 (M Dose) Table 42. Global Osteoarthritis Pain Drugs Sales by Region (2021-2026) & (M Dose) Table 43. Global Osteoarthritis Pain Drugs Sales Market Share by Region (2021-2026) Table 44. Global Osteoarthritis Pain Drugs Sales Forecasted by Region (2027-2032) & (M Dose) Table 45. Global Osteoarthritis Pain Drugs Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Osteoarthritis Pain Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Dose) Table 47. North America Osteoarthritis Pain Drugs Sales by Country (2021-2026) & (M Dose) Table 48. North America Osteoarthritis Pain Drugs Sales by Country (2027-2032) & (M Dose) Table 49. Europe Osteoarthritis Pain Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Dose) Table 50. Europe Osteoarthritis Pain Drugs Sales by Country (2021-2026) & (M Dose) Table 51. Europe Osteoarthritis Pain Drugs Sales by Country (2027-2032) & (M Dose) Table 52. Asia Pacific Osteoarthritis Pain Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Dose) Table 53. Asia Pacific Osteoarthritis Pain Drugs Sales by Country (2021-2026) & (M Dose) Table 54. Asia Pacific Osteoarthritis Pain Drugs Sales by Country (2027-2032) & (M Dose) Table 55. South America, Middle East and Africa Osteoarthritis Pain Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Dose) Table 56. South America, Middle East and Africa Osteoarthritis Pain Drugs Sales by Country (2021-2026) & (M Dose) Table 57. South America, Middle East and Africa Osteoarthritis Pain Drugs Sales by Country (2027-2032) & (M Dose) Table 58. Global Osteoarthritis Pain Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Osteoarthritis Pain Drugs Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Osteoarthritis Pain Drugs Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Osteoarthritis Pain Drugs Revenue Market Share by Region (2021-2026) Table 62. Global Osteoarthritis Pain Drugs Revenue Market Share by Region (2027-2032) Table 63. Pfizer Company Information Table 64. Pfizer Business Overview Table 65. Pfizer Osteoarthritis Pain Drugs Sales (M Dose), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Pfizer Osteoarthritis Pain Drugs Product Portfolio Table 67. Pfizer Recent Development Table 68. Bayer Company Information Table 69. Bayer Business Overview Table 70. Bayer Osteoarthritis Pain Drugs Sales (M Dose), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Bayer Osteoarthritis Pain Drugs Product Portfolio Table 72. Bayer Recent Development Table 73. SK Chemicals Company Information Table 74. SK Chemicals Business Overview Table 75. SK Chemicals Osteoarthritis Pain Drugs Sales (M Dose), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. SK Chemicals Osteoarthritis Pain Drugs Product Portfolio Table 77. SK Chemicals Recent Development Table 78. GSK Company Information Table 79. GSK Business Overview Table 80. GSK Osteoarthritis Pain Drugs Sales (M Dose), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. GSK Osteoarthritis Pain Drugs Product Portfolio Table 82. GSK Recent Development Table 83. Sanofi Company Information Table 84. Sanofi Business Overview Table 85. Sanofi Osteoarthritis Pain Drugs Sales (M Dose), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Sanofi Osteoarthritis Pain Drugs Product Portfolio Table 87. Sanofi Recent Development Table 88. Crystal Genomics Company Information Table 89. Crystal Genomics Business Overview Table 90. Crystal Genomics Osteoarthritis Pain Drugs Sales (M Dose), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Crystal Genomics Osteoarthritis Pain Drugs Product Portfolio Table 92. Crystal Genomics Recent Development Table 93. Johnson & Johnson Company Information Table 94. Johnson & Johnson Business Overview Table 95. Johnson & Johnson Osteoarthritis Pain Drugs Sales (M Dose), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Johnson & Johnson Osteoarthritis Pain Drugs Product Portfolio Table 97. Johnson & Johnson Recent Development Table 98. Sino Biopharmaceutical Company Information Table 99. Sino Biopharmaceutical Business Overview Table 100. Sino Biopharmaceutical Osteoarthritis Pain Drugs Sales (M Dose), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Sino Biopharmaceutical Osteoarthritis Pain Drugs Product Portfolio Table 102. Sino Biopharmaceutical Recent Development Table 103. Haohai Biological Company Information Table 104. Haohai Biological Business Overview Table 105. Haohai Biological Osteoarthritis Pain Drugs Sales (M Dose), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Haohai Biological Osteoarthritis Pain Drugs Product Portfolio Table 107. Haohai Biological Recent Development Table 108. Zhejiang Chengyi Pharmaceutical Company Information Table 109. Zhejiang Chengyi Pharmaceutical Business Overview Table 110. Zhejiang Chengyi Pharmaceutical Osteoarthritis Pain Drugs Sales (M Dose), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Zhejiang Chengyi Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio Table 112. Zhejiang Chengyi Pharmaceutical Recent Development Table 113. Freda Company Information Table 114. Freda Business Overview Table 115. Freda Osteoarthritis Pain Drugs Sales (M Dose), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Freda Osteoarthritis Pain Drugs Product Portfolio Table 117. Freda Recent Development Table 118. Bright Future Company Information Table 119. Bright Future Business Overview Table 120. Bright Future Osteoarthritis Pain Drugs Sales (M Dose), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Bright Future Osteoarthritis Pain Drugs Product Portfolio Table 122. Bright Future Recent Development Table 123. Jingfeng Pharmaceutical Company Information Table 124. Jingfeng Pharmaceutical Business Overview Table 125. Jingfeng Pharmaceutical Osteoarthritis Pain Drugs Sales (M Dose), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Jingfeng Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio Table 127. Jingfeng Pharmaceutical Recent Development Table 128. Chugai Pharmaceutical Company Information Table 129. Chugai Pharmaceutical Business Overview Table 130. Chugai Pharmaceutical Osteoarthritis Pain Drugs Sales (M Dose), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 131. Chugai Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio Table 132. Chugai Pharmaceutical Recent Development Table 133. Mikasa Seiyaku Company Information Table 134. Mikasa Seiyaku Business Overview Table 135. Mikasa Seiyaku Osteoarthritis Pain Drugs Sales (M Dose), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 136. Mikasa Seiyaku Osteoarthritis Pain Drugs Product Portfolio Table 137. Mikasa Seiyaku Recent Development Table 138. Taisho Pharmaceutical Company Information Table 139. Taisho Pharmaceutical Business Overview Table 140. Taisho Pharmaceutical Osteoarthritis Pain Drugs Sales (M Dose), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 141. Taisho Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio Table 142. Taisho Pharmaceutical Recent Development Table 143. Seikagaku Corporation Company Information Table 144. Seikagaku Corporation Business Overview Table 145. Seikagaku Corporation Osteoarthritis Pain Drugs Sales (M Dose), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 146. Seikagaku Corporation Osteoarthritis Pain Drugs Product Portfolio Table 147. Seikagaku Corporation Recent Development Table 148. GlaxoSmithKline Company Information Table 149. GlaxoSmithKline Business Overview Table 150. GlaxoSmithKline Osteoarthritis Pain Drugs Sales (M Dose), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 151. GlaxoSmithKline Osteoarthritis Pain Drugs Product Portfolio Table 152. GlaxoSmithKline Recent Development Table 153. Eli Lilly Company Information Table 154. Eli Lilly Business Overview Table 155. Eli Lilly Osteoarthritis Pain Drugs Sales (M Dose), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 156. Eli Lilly Osteoarthritis Pain Drugs Product Portfolio Table 157. Eli Lilly Recent Development Table 158. Novartis Company Information Table 159. Novartis Business Overview Table 160. Novartis Osteoarthritis Pain Drugs Sales (M Dose), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 161. Novartis Osteoarthritis Pain Drugs Product Portfolio Table 162. Novartis Recent Development Table 163. Horizon Pharma Company Information Table 164. Horizon Pharma Business Overview Table 165. Horizon Pharma Osteoarthritis Pain Drugs Sales (M Dose), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 166. Horizon Pharma Osteoarthritis Pain Drugs Product Portfolio Table 167. Horizon Pharma Recent Development Table 168. Abbott Company Information Table 169. Abbott Business Overview Table 170. Abbott Osteoarthritis Pain Drugs Sales (M Dose), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 171. Abbott Osteoarthritis Pain Drugs Product Portfolio Table 172. Abbott Recent Development Table 173. Mylan Company Information Table 174. Mylan Business Overview Table 175. Mylan Osteoarthritis Pain Drugs Sales (M Dose), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 176. Mylan Osteoarthritis Pain Drugs Product Portfolio Table 177. Mylan Recent Development Table 178. Daiichi Sankyo Company Information Table 179. Daiichi Sankyo Business Overview Table 180. Daiichi Sankyo Osteoarthritis Pain Drugs Sales (M Dose), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 181. Daiichi Sankyo Osteoarthritis Pain Drugs Product Portfolio Table 182. Daiichi Sankyo Recent Development Table 183. TEVA Company Information Table 184. TEVA Business Overview Table 185. TEVA Osteoarthritis Pain Drugs Sales (M Dose), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 186. TEVA Osteoarthritis Pain Drugs Product Portfolio Table 187. TEVA Recent Development Table 188. Almatica Pharma Company Information Table 189. Almatica Pharma Business Overview Table 190. Almatica Pharma Osteoarthritis Pain Drugs Sales (M Dose), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 191. Almatica Pharma Osteoarthritis Pain Drugs Product Portfolio Table 192. Almatica Pharma Recent Development Table 193. Astellas Pharma Company Information Table 194. Astellas Pharma Business Overview Table 195. Astellas Pharma Osteoarthritis Pain Drugs Sales (M Dose), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 196. Astellas Pharma Osteoarthritis Pain Drugs Product Portfolio Table 197. Astellas Pharma Recent Development Table 198. Tide Pharmaceutical Company Information Table 199. Tide Pharmaceutical Business Overview Table 200. Tide Pharmaceutical Osteoarthritis Pain Drugs Sales (M Dose), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 201. Tide Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio Table 202. Tide Pharmaceutical Recent Development Table 203. Iroko Pharmaceuticals Company Information Table 204. Iroko Pharmaceuticals Business Overview Table 205. Iroko Pharmaceuticals Osteoarthritis Pain Drugs Sales (M Dose), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 206. Iroko Pharmaceuticals Osteoarthritis Pain Drugs Product Portfolio Table 207. Iroko Pharmaceuticals Recent Development Table 208. Hengrui Pharmaceutical Company Information Table 209. Hengrui Pharmaceutical Business Overview Table 210. Hengrui Pharmaceutical Osteoarthritis Pain Drugs Sales (M Dose), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 211. Hengrui Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio Table 212. Hengrui Pharmaceutical Recent Development Table 213. Key Raw Materials Table 214. Raw Materials Key Suppliers Table 215. Osteoarthritis Pain Drugs Distributors List Table 216. Osteoarthritis Pain Drugs Customers List Table 217. Research Programs/Design for This Report Table 218. Authors List of This Report Table 219. Secondary Sources Table 220. Primary Sources List of Figures Figure 1. Osteoarthritis Pain Drugs Product Image Figure 2. Global Osteoarthritis Pain Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Osteoarthritis Pain Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Osteoarthritis Pain Drugs Sales (2021-2032) & (M Dose) Figure 5. Global Osteoarthritis Pain Drugs Average Price (US$/Dose) & (2021-2032) Figure 6. Global Top 5 and 10 Osteoarthritis Pain Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Oral Image Figure 9. Injection Image Figure 10. External Image Figure 11. Global Osteoarthritis Pain Drugs Sales by Type (2021 VS 2025 VS 2032) & (M Dose) Figure 12. Global Osteoarthritis Pain Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Osteoarthritis Pain Drugs Sales Market Share by Type (2021-2032) Figure 14. Global Osteoarthritis Pain Drugs Revenue by Type (2021 VS 2025 VS 2032) & (M Dose) Figure 15. Global Osteoarthritis Pain Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Osteoarthritis Pain Drugs Revenue Market Share by Type (2021-2032) Figure 17. Medical Care Image Figure 18. Personal Care Image Figure 19. Global Osteoarthritis Pain Drugs Sales by Application (2021 VS 2025 VS 2032) & (M Dose) Figure 20. Global Osteoarthritis Pain Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Osteoarthritis Pain Drugs Sales Market Share by Application (2021-2032) Figure 22. Global Osteoarthritis Pain Drugs Revenue by Application (2021 VS 2025 VS 2032) & (M Dose) Figure 23. Global Osteoarthritis Pain Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Osteoarthritis Pain Drugs Revenue Market Share by Application (2021-2032) Figure 25. North America Osteoarthritis Pain Drugs Sales and Growth Rate (2021-2032) & (M Dose) Figure 26. North America Osteoarthritis Pain Drugs Sales Market Share by Country (2021-2032) Figure 27. U.S. Osteoarthritis Pain Drugs Sales and Growth Rate (2021-2032) & (M Dose) Figure 28. Canada Osteoarthritis Pain Drugs Sales and Growth Rate (2021-2032) & (M Dose) Figure 29. Mexico Osteoarthritis Pain Drugs Sales and Growth Rate (2021-2032) & (M Dose) Figure 30. Europe Osteoarthritis Pain Drugs Sales and Growth Rate (2021-2032) & (M Dose) Figure 31. Europe Osteoarthritis Pain Drugs Sales Market Share by Country (2021-2032) Figure 32. Germany Osteoarthritis Pain Drugs Sales and Growth Rate (2021-2032) & (M Dose) Figure 33. France Osteoarthritis Pain Drugs Sales and Growth Rate (2021-2032) & (M Dose) Figure 34. U.K. Osteoarthritis Pain Drugs Sales and Growth Rate (2021-2032) & (M Dose) Figure 35. Italy Osteoarthritis Pain Drugs Sales and Growth Rate (2021-2032) & (M Dose) Figure 36. Netherlands Osteoarthritis Pain Drugs Sales and Growth Rate (2021-2032) & (M Dose) Figure 37. Asia Pacific Osteoarthritis Pain Drugs Sales and Growth Rate (2021-2032) & (M Dose) Figure 38. Asia Pacific Osteoarthritis Pain Drugs Sales Market Share by Country (2021-2032) Figure 39. China Osteoarthritis Pain Drugs Sales and Growth Rate (2021-2032) & (M Dose) Figure 40. Japan Osteoarthritis Pain Drugs Sales and Growth Rate (2021-2032) & (M Dose) Figure 41. South Korea Osteoarthritis Pain Drugs Sales and Growth Rate (2021-2032) & (M Dose) Figure 42. Southeast Asia Osteoarthritis Pain Drugs Sales and Growth Rate (2021-2032) & (M Dose) Figure 43. India Osteoarthritis Pain Drugs Sales and Growth Rate (2021-2032) & (M Dose) Figure 44. Australia Osteoarthritis Pain Drugs Sales and Growth Rate (2021-2032) & (M Dose) Figure 45. South America, Middle East and Africa Osteoarthritis Pain Drugs Sales and Growth Rate (2021-2032) & (M Dose) Figure 46. South America, Middle East and Africa Osteoarthritis Pain Drugs Sales Market Share by Country (2021-2032) Figure 47. Brazil Osteoarthritis Pain Drugs Sales and Growth Rate (2021-2032) & (M Dose) Figure 48. South Africa Osteoarthritis Pain Drugs Sales and Growth Rate (2021-2032) & (M Dose) Figure 49. Saudi Arabia Osteoarthritis Pain Drugs Sales and Growth Rate (2021-2032) & (M Dose) Figure 50. Turkey Osteoarthritis Pain Drugs Sales and Growth Rate (2021-2032) & (M Dose) Figure 51. Argentina Osteoarthritis Pain Drugs Sales and Growth Rate (2021-2032) & (M Dose) Figure 52. UAE Osteoarthritis Pain Drugs Sales and Growth Rate (2021-2032) & (M Dose) Figure 53. Egypt Osteoarthritis Pain Drugs Sales and Growth Rate (2021-2032) & (M Dose) Figure 54. Chile Osteoarthritis Pain Drugs Sales and Growth Rate (2021-2032) & (M Dose) Figure 55. Global Osteoarthritis Pain Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Osteoarthritis Pain Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Osteoarthritis Pain Drugs Revenue (2021-2032) & (US$ Million) Figure 58. North America Osteoarthritis Pain Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Osteoarthritis Pain Drugs Revenue (2021-2032) & (US$ Million) Figure 60. Europe Osteoarthritis Pain Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Osteoarthritis Pain Drugs Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Osteoarthritis Pain Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Osteoarthritis Pain Drugs Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Osteoarthritis Pain Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Osteoarthritis Pain Drugs Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Osteoarthritis Pain Drugs Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Oral
  • Injection
  • External
Applications
  • Medical Care
  • Personal Care
Companies covered
  • Pfizer
  • Bayer
  • SK Chemicals
  • GSK
  • Sanofi
  • Crystal Genomics
  • Johnson & Johnson
  • Sino Biopharmaceutical
  • Haohai Biological
  • Zhejiang Chengyi Pharmaceutical
  • Freda
  • Bright Future
  • Jingfeng Pharmaceutical
  • Chugai Pharmaceutical
  • Mikasa Seiyaku
  • Taisho Pharmaceutical
  • Seikagaku Corporation
  • GlaxoSmithKline
  • Eli Lilly
  • Novartis
  • Horizon Pharma
  • Abbott
  • Mylan
  • Daiichi Sankyo
  • TEVA
  • Almatica Pharma
  • Astellas Pharma
  • Tide Pharmaceutical
  • Iroko Pharmaceuticals
  • Hengrui Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Osteoarthritis Pain Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Osteoarthritis Pain Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Osteoarthritis Pain Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Osteoarthritis Pain Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Osteoarthritis Pain Drugs Market Dynamics
  1. 2.1 Osteoarthritis Pain Drugs Industry Trends
  2. 2.2 Osteoarthritis Pain Drugs Industry Drivers
  3. 2.3 Osteoarthritis Pain Drugs Industry Opportunities and Challenges
  4. 2.4 Osteoarthritis Pain Drugs Industry Restraints
3 Osteoarthritis Pain Drugs Market by Manufacturers
  1. 3.1 Global Osteoarthritis Pain Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Osteoarthritis Pain Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Osteoarthritis Pain Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Osteoarthritis Pain Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Osteoarthritis Pain Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Osteoarthritis Pain Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Osteoarthritis Pain Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Osteoarthritis Pain Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Osteoarthritis Pain Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Osteoarthritis Pain Drugs Tier 1, Tier 2, and Tier 3
4 Osteoarthritis Pain Drugs Market by Type
  1. 4.1 Osteoarthritis Pain Drugs Type Introduction
  2. 4.1.1 Oral
  3. 4.1.2 Injection
  4. 4.1.3 External
  5. 4.2 Global Osteoarthritis Pain Drugs Sales by Type
  6. 4.2.1 Global Osteoarthritis Pain Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Osteoarthritis Pain Drugs Sales by Type (2021-2032)
  8. 4.2.3 Global Osteoarthritis Pain Drugs Sales Market Share by Type (2021-2032)
  9. 4.3 Global Osteoarthritis Pain Drugs Revenue by Type
  10. 4.3.1 Global Osteoarthritis Pain Drugs Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Osteoarthritis Pain Drugs Revenue by Type (2021-2032)
  12. 4.3.3 Global Osteoarthritis Pain Drugs Revenue Market Share by Type (2021-2032)
5 Osteoarthritis Pain Drugs Market by Application
  1. 5.1 Osteoarthritis Pain Drugs Application Introduction
  2. 5.1.1 Medical Care
  3. 5.1.2 Personal Care
  4. 5.2 Global Osteoarthritis Pain Drugs Sales by Application
  5. 5.2.1 Global Osteoarthritis Pain Drugs Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Osteoarthritis Pain Drugs Sales by Application (2021-2032)
  7. 5.2.3 Global Osteoarthritis Pain Drugs Sales Market Share by Application (2021-2032)
  8. 5.3 Global Osteoarthritis Pain Drugs Revenue by Application
  9. 5.3.1 Global Osteoarthritis Pain Drugs Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Osteoarthritis Pain Drugs Revenue by Application (2021-2032)
  11. 5.3.3 Global Osteoarthritis Pain Drugs Revenue Market Share by Application (2021-2032)
6 Global Osteoarthritis Pain Drugs Sales by Region
  1. 6.1 Global Osteoarthritis Pain Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Osteoarthritis Pain Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Osteoarthritis Pain Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Osteoarthritis Pain Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Osteoarthritis Pain Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Osteoarthritis Pain Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Osteoarthritis Pain Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Osteoarthritis Pain Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Osteoarthritis Pain Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Osteoarthritis Pain Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Osteoarthritis Pain Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Osteoarthritis Pain Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Osteoarthritis Pain Drugs Revenue by Region
  1. 7.1 Global Osteoarthritis Pain Drugs Revenue by Region
  2. 7.1.1 Global Osteoarthritis Pain Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Osteoarthritis Pain Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Osteoarthritis Pain Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Osteoarthritis Pain Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Osteoarthritis Pain Drugs Revenue (2021-2032)
  8. 7.2.2 North America Osteoarthritis Pain Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Osteoarthritis Pain Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Osteoarthritis Pain Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Osteoarthritis Pain Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Osteoarthritis Pain Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Osteoarthritis Pain Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Osteoarthritis Pain Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Pfizer
  2. 8.1.1 Pfizer Company Information
  3. 8.1.2 Pfizer Business Overview
  4. 8.1.3 Pfizer Osteoarthritis Pain Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Pfizer Osteoarthritis Pain Drugs Product Portfolio
  6. 8.1.5 Pfizer Recent Developments
  7. 8.2 Bayer
  8. 8.2.1 Bayer Company Information
  9. 8.2.2 Bayer Business Overview
  10. 8.2.3 Bayer Osteoarthritis Pain Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bayer Osteoarthritis Pain Drugs Product Portfolio
  12. 8.2.5 Bayer Recent Developments
  13. 8.3 SK Chemicals
  14. 8.3.1 SK Chemicals Company Information
  15. 8.3.2 SK Chemicals Business Overview
  16. 8.3.3 SK Chemicals Osteoarthritis Pain Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 SK Chemicals Osteoarthritis Pain Drugs Product Portfolio
  18. 8.3.5 SK Chemicals Recent Developments
  19. 8.4 GSK
  20. 8.4.1 GSK Company Information
  21. 8.4.2 GSK Business Overview
  22. 8.4.3 GSK Osteoarthritis Pain Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 GSK Osteoarthritis Pain Drugs Product Portfolio
  24. 8.4.5 GSK Recent Developments
  25. 8.5 Sanofi
  26. 8.5.1 Sanofi Company Information
  27. 8.5.2 Sanofi Business Overview
  28. 8.5.3 Sanofi Osteoarthritis Pain Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sanofi Osteoarthritis Pain Drugs Product Portfolio
  30. 8.5.5 Sanofi Recent Developments
  31. 8.6 Crystal Genomics
  32. 8.6.1 Crystal Genomics Company Information
  33. 8.6.2 Crystal Genomics Business Overview
  34. 8.6.3 Crystal Genomics Osteoarthritis Pain Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Crystal Genomics Osteoarthritis Pain Drugs Product Portfolio
  36. 8.6.5 Crystal Genomics Recent Developments
  37. 8.7 Johnson & Johnson
  38. 8.7.1 Johnson & Johnson Company Information
  39. 8.7.2 Johnson & Johnson Business Overview
  40. 8.7.3 Johnson & Johnson Osteoarthritis Pain Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Johnson & Johnson Osteoarthritis Pain Drugs Product Portfolio
  42. 8.7.5 Johnson & Johnson Recent Developments
  43. 8.8 Sino Biopharmaceutical
  44. 8.8.1 Sino Biopharmaceutical Company Information
  45. 8.8.2 Sino Biopharmaceutical Business Overview
  46. 8.8.3 Sino Biopharmaceutical Osteoarthritis Pain Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Sino Biopharmaceutical Osteoarthritis Pain Drugs Product Portfolio
  48. 8.8.5 Sino Biopharmaceutical Recent Developments
  49. 8.9 Haohai Biological
  50. 8.9.1 Haohai Biological Company Information
  51. 8.9.2 Haohai Biological Business Overview
  52. 8.9.3 Haohai Biological Osteoarthritis Pain Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Haohai Biological Osteoarthritis Pain Drugs Product Portfolio
  54. 8.9.5 Haohai Biological Recent Developments
  55. 8.10 Zhejiang Chengyi Pharmaceutical
  56. 8.10.1 Zhejiang Chengyi Pharmaceutical Company Information
  57. 8.10.2 Zhejiang Chengyi Pharmaceutical Business Overview
  58. 8.10.3 Zhejiang Chengyi Pharmaceutical Osteoarthritis Pain Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Zhejiang Chengyi Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio
  60. 8.10.5 Zhejiang Chengyi Pharmaceutical Recent Developments
  61. 8.11 Freda
  62. 8.11.1 Freda Company Information
  63. 8.11.2 Freda Business Overview
  64. 8.11.3 Freda Osteoarthritis Pain Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Freda Osteoarthritis Pain Drugs Product Portfolio
  66. 8.11.5 Freda Recent Developments
  67. 8.12 Bright Future
  68. 8.12.1 Bright Future Company Information
  69. 8.12.2 Bright Future Business Overview
  70. 8.12.3 Bright Future Osteoarthritis Pain Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Bright Future Osteoarthritis Pain Drugs Product Portfolio
  72. 8.12.5 Bright Future Recent Developments
  73. 8.13 Jingfeng Pharmaceutical
  74. 8.13.1 Jingfeng Pharmaceutical Company Information
  75. 8.13.2 Jingfeng Pharmaceutical Business Overview
  76. 8.13.3 Jingfeng Pharmaceutical Osteoarthritis Pain Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Jingfeng Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio
  78. 8.13.5 Jingfeng Pharmaceutical Recent Developments
  79. 8.14 Chugai Pharmaceutical
  80. 8.14.1 Chugai Pharmaceutical Company Information
  81. 8.14.2 Chugai Pharmaceutical Business Overview
  82. 8.14.3 Chugai Pharmaceutical Osteoarthritis Pain Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Chugai Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio
  84. 8.14.5 Chugai Pharmaceutical Recent Developments
  85. 8.15 Mikasa Seiyaku
  86. 8.15.1 Mikasa Seiyaku Company Information
  87. 8.15.2 Mikasa Seiyaku Business Overview
  88. 8.15.3 Mikasa Seiyaku Osteoarthritis Pain Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Mikasa Seiyaku Osteoarthritis Pain Drugs Product Portfolio
  90. 8.15.5 Mikasa Seiyaku Recent Developments
  91. 8.16 Taisho Pharmaceutical
  92. 8.16.1 Taisho Pharmaceutical Company Information
  93. 8.16.2 Taisho Pharmaceutical Business Overview
  94. 8.16.3 Taisho Pharmaceutical Osteoarthritis Pain Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Taisho Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio
  96. 8.16.5 Taisho Pharmaceutical Recent Developments
  97. 8.17 Seikagaku Corporation
  98. 8.17.1 Seikagaku Corporation Company Information
  99. 8.17.2 Seikagaku Corporation Business Overview
  100. 8.17.3 Seikagaku Corporation Osteoarthritis Pain Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Seikagaku Corporation Osteoarthritis Pain Drugs Product Portfolio
  102. 8.17.5 Seikagaku Corporation Recent Developments
  103. 8.18 GlaxoSmithKline
  104. 8.18.1 GlaxoSmithKline Company Information
  105. 8.18.2 GlaxoSmithKline Business Overview
  106. 8.18.3 GlaxoSmithKline Osteoarthritis Pain Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 GlaxoSmithKline Osteoarthritis Pain Drugs Product Portfolio
  108. 8.18.5 GlaxoSmithKline Recent Developments
  109. 8.19 Eli Lilly
  110. 8.19.1 Eli Lilly Company Information
  111. 8.19.2 Eli Lilly Business Overview
  112. 8.19.3 Eli Lilly Osteoarthritis Pain Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Eli Lilly Osteoarthritis Pain Drugs Product Portfolio
  114. 8.19.5 Eli Lilly Recent Developments
  115. 8.20 Novartis
  116. 8.20.1 Novartis Company Information
  117. 8.20.2 Novartis Business Overview
  118. 8.20.3 Novartis Osteoarthritis Pain Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Novartis Osteoarthritis Pain Drugs Product Portfolio
  120. 8.20.5 Novartis Recent Developments
  121. 8.21 Horizon Pharma
  122. 8.21.1 Horizon Pharma Company Information
  123. 8.21.2 Horizon Pharma Business Overview
  124. 8.21.3 Horizon Pharma Osteoarthritis Pain Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Horizon Pharma Osteoarthritis Pain Drugs Product Portfolio
  126. 8.21.5 Horizon Pharma Recent Developments
  127. 8.22 Abbott
  128. 8.22.1 Abbott Company Information
  129. 8.22.2 Abbott Business Overview
  130. 8.22.3 Abbott Osteoarthritis Pain Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Abbott Osteoarthritis Pain Drugs Product Portfolio
  132. 8.22.5 Abbott Recent Developments
  133. 8.23 Mylan
  134. 8.23.1 Mylan Company Information
  135. 8.23.2 Mylan Business Overview
  136. 8.23.3 Mylan Osteoarthritis Pain Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  137. 8.23.4 Mylan Osteoarthritis Pain Drugs Product Portfolio
  138. 8.23.5 Mylan Recent Developments
  139. 8.24 Daiichi Sankyo
  140. 8.24.1 Daiichi Sankyo Company Information
  141. 8.24.2 Daiichi Sankyo Business Overview
  142. 8.24.3 Daiichi Sankyo Osteoarthritis Pain Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  143. 8.24.4 Daiichi Sankyo Osteoarthritis Pain Drugs Product Portfolio
  144. 8.24.5 Daiichi Sankyo Recent Developments
  145. 8.25 TEVA
  146. 8.25.1 TEVA Company Information
  147. 8.25.2 TEVA Business Overview
  148. 8.25.3 TEVA Osteoarthritis Pain Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  149. 8.25.4 TEVA Osteoarthritis Pain Drugs Product Portfolio
  150. 8.25.5 TEVA Recent Developments
  151. 8.26 Almatica Pharma
  152. 8.26.1 Almatica Pharma Company Information
  153. 8.26.2 Almatica Pharma Business Overview
  154. 8.26.3 Almatica Pharma Osteoarthritis Pain Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  155. 8.26.4 Almatica Pharma Osteoarthritis Pain Drugs Product Portfolio
  156. 8.26.5 Almatica Pharma Recent Developments
  157. 8.27 Astellas Pharma
  158. 8.27.1 Astellas Pharma Company Information
  159. 8.27.2 Astellas Pharma Business Overview
  160. 8.27.3 Astellas Pharma Osteoarthritis Pain Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  161. 8.27.4 Astellas Pharma Osteoarthritis Pain Drugs Product Portfolio
  162. 8.27.5 Astellas Pharma Recent Developments
  163. 8.28 Tide Pharmaceutical
  164. 8.28.1 Tide Pharmaceutical Company Information
  165. 8.28.2 Tide Pharmaceutical Business Overview
  166. 8.28.3 Tide Pharmaceutical Osteoarthritis Pain Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  167. 8.28.4 Tide Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio
  168. 8.28.5 Tide Pharmaceutical Recent Developments
  169. 8.29 Iroko Pharmaceuticals
  170. 8.29.1 Iroko Pharmaceuticals Company Information
  171. 8.29.2 Iroko Pharmaceuticals Business Overview
  172. 8.29.3 Iroko Pharmaceuticals Osteoarthritis Pain Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  173. 8.29.4 Iroko Pharmaceuticals Osteoarthritis Pain Drugs Product Portfolio
  174. 8.29.5 Iroko Pharmaceuticals Recent Developments
  175. 8.30 Hengrui Pharmaceutical
  176. 8.30.1 Hengrui Pharmaceutical Company Information
  177. 8.30.2 Hengrui Pharmaceutical Business Overview
  178. 8.30.3 Hengrui Pharmaceutical Osteoarthritis Pain Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  179. 8.30.4 Hengrui Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio
  180. 8.30.5 Hengrui Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Osteoarthritis Pain Drugs Value Chain Analysis
  2. 9.1.1 Osteoarthritis Pain Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Osteoarthritis Pain Drugs Production Mode & Process
  6. 9.2 Osteoarthritis Pain Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Osteoarthritis Pain Drugs Distributors
  9. 9.2.3 Osteoarthritis Pain Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst